US3949088A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted phenoxy propanol amines used for treating cardiovascular diseases
Assignee: Individual
•
Filing: 1974-04-16
•
Granted: 1976-04-06
•
Expires: 1994-04-16
Abstract
Abstract A new amine of the formula ##EQU1## wherein R 1 is loweralkylthio loweralkyl, loweralkoxy loweralkoxy, loweralkylcarbonylamino loweralkyl or loweralkoxycarbonylamino loweralkyl, R 2 is benzyl, phenoxyloweralkyl, cyano or the group ##EQU2## wherein R 3 and R 4 are hydrogen or loweralkyl and R 5 is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkinyl, loweralkoxymethyl, loweralkoxy, loweralkenyloxy or loweralkinyloxy, a pharmaceutical preparation containing the same and a method for treating cardiovascular diseases.
Inventors
- 👤 Benny Roger Samuelsson
- 👤 Gert Christer Strandlund
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 17:31
CPC Classifications
C; C07; C07C; C07C323/00; C07C323/10; C07C323/11; C07C323/16; C07C237/00; C07C237/02; C07C237/04; C07C237/06; C07C255/00; C07C255/01; C07C255/24; C07C271/00; C07C271/06; C07C271/08; C07C271/10; C07C271/16
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
88 words
A method for blocking adrenergic β-receptor stimulation in the treatment of cardiovascular diseases, comprising administering to a mammal in which a β-receptor blockade is desired an amount, effective to provide antagonism to adrenergic β-receptor stimulation, of a compound of formula I ##EQU27## wherein R 1 is a loweralkylthio loweralkyl, loweralkoxy loweralkoxy, R 2 is a group ##EQU28## wherein R 3 and R 4 are hydrogen or loweralkyl and R 5 is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkinyl, loweralkoxy-methyl, loweralkoxy, loweralkenyloxy or loweralkinyloxy or its therapeutically acceptable acid addition salt.
Claim 2
Independent Claim
88 words
A method for blocking adrenergic β-receptor stimulation in the treatment of cardiovascular diseases, comprising administering to a mammal in which a β-receptor blockade is desired an amount, effective to provide antagonism to adrenergic β-receptor stimulation, of a compound of formula I ##EQU27## wherein R 1 is a loweralkylthio loweralkyl, loweralkoxy loweralkoxy, R 2 is a group ##EQU28## wherein R 3 and R 4 are hydrogen or loweralkyl and R 5 is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkinyl, loweralkoxy-methyl, loweralkoxy, loweralkenyloxy or loweralkinyloxy or its therapeutically acceptable acid addition salt.
Claim 3
Dependent Claim
40 words
A method according to claim 1 wherein said compound has the formula Ia ##EQU29## wherein R 1a is a loweralkylthio loweralkyl, R 2a is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl and R 5a is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkoxy-methyl, loweralkoxy or loweralkenyloxy.
Claim 4
Dependent Claim
31 words
A method according to claim 1 wherein R 1a is loweralkylthioloweralkyl, R 2a is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl, and R 5a is hydrogen, chloro, bromo, methyl, allyl, methoxymethyl, methoxy or allyloxy.
Claim 5
Dependent Claim
22 words
A method according to claim 1 wherein R 1a is 2-methylthioethyl, R 2a is carbamoyl or methylcarbamoyl, and R 5a is hydrogen.
Claim 6
Dependent Claim
39 words
A method according to claim 1 wherein said compound has a formula Ib ##EQU30## wherein R 1b is loweralkoxy loweralkoxy, R 2b is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl and R 5b is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkoxymethyl, loweralkoxy or loweralkenyloxy.
Claim 7
Dependent Claim
34 words
A method according to claim 5 wherein R 1b is 2-ethoxyethoxy, 2-methoxyethoxy or 3-methoxy-n-propoxy, R 2b is carbamoyl, methylcarbamoyl or dimethylcarbamoyl, and R 5b is hydrogen, chloro, bromo, methyl, allyl, methoxymethyl, methoxy or allyloxy.
Claim 8
Dependent Claim
22 words
A method according to claim 5 wherein R 1b is 2-methoxyethoxy, R 2b is carbamoyl or N-methylcarbamoyl and R 5b is hydrogen.
Claim 9
Dependent Claim
18 words
A method according to claim 1 wherein said compound is in the form of a dextro-rotating optical antipode.
Claim 10
Dependent Claim
18 words
A method according to claim 1 wherein said compound is in the form of its levo-rotating optical antipode.
Claim 11
Dependent Claim
15 words
A method according to claim 1 wherein said compound is in a free base form.
Claim 12
Dependent Claim
20 words
A method according to claim 1 wherein said compound is in the form of a therapeutically acceptable acid addition salt.
Claim 13
Dependent Claim
11 words
A method according to claim 1 wherein said compound is 1-[4-(2-methoxyethoxy)-phenoxy]-2-hydroxy-3-[2-(N-methyl)-carbamoyl-1-methylethyl]-aminopropane.
Claim 14
Dependent Claim
11 words
A method according to claim 1 wherein said compound if 1-[4-(2-methoxyethoxy-phenoxy]-2-hydroxy-3-(1-methyl-2-carbamoylethyl)-aminopropane.
Claim 15
Dependent Claim
87 words
A pharmaceutical composition useful for blocking adrenergic B-receptor stimulation in the treatment of cardiovascular diseases containing a compound of formula I ##EQU31## wherein R 1 is a loweralkylthio loweralkyl, loweralkoxy loweralkoxy, R 2 is a group ##EQU32## wherein R 3 and R 4 are hydrogen or loweralkyl and R 5 is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkinyl, loweralkoxy-methyl, loweralkoxy, loweralkenyloxy or loweralkinyloxy or its therapeutically acceptable acid addition salt and a therapeutically acceptable carrier therefor, said composition containing from 0.1 to 95% by weight of said compound I.
Claim 16
Dependent Claim
87 words
A pharmaceutical composition useful for blocking adrenergic B-receptor stimulation in the treatment of cardiovascular diseases containing a compound of formula I ##EQU31## wherein R 1 is a loweralkylthio loweralkyl, loweralkoxy loweralkoxy, R 2 is a group ##EQU32## wherein R 3 and R 4 are hydrogen or loweralkyl and R 5 is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkinyl, loweralkoxy-methyl, loweralkoxy, loweralkenyloxy or loweralkinyloxy or its therapeutically acceptable acid addition salt and a therapeutically acceptable carrier therefor, said composition containing from 0.1 to 95% by weight of said compound I.
Claim 17
Dependent Claim
30 words
A pharmaceutical composition according to claim 14 in a form suitable for administration by injection wherein said compound I comprises about 0.5 to about 20% by weight of said composition.
Claim 18
Dependent Claim
29 words
A pharmaceutical composition according to claim 14 in a form suitable for oral administration wherein said compound I comprises about 2% to about 50% by weight of said composition.
Claim 19
Dependent Claim
41 words
A pharmaceutical composition according to claim 14 wherein said compound has the formula Ia ##EQU33## wherein R 1a is a loweralkylthio loweralkyl, R 2a is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl and R 5a is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkoxy-methyl, loweralkoxy or loweralkenyloxy.
Claim 20
Dependent Claim
32 words
A pharmaceutical composition according to claim 11 wherein R 1a is loweralkylthioloweralkyl, R 2a is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl, and R 5a is hydrogen, chloro, bromo, methyl, allyl, methoxymethyl, methoxy or allyloxy.
Claim 21
Dependent Claim
23 words
A pharmaceutical composition according to claim 17 wherein R 1a is 2-methylthioethyl, R 2a is carbamoyl or methylcarbamoyl, and R 5a is hydrogen.
Claim 22
Dependent Claim
40 words
A pharmaceutical composition according to claim 14 wherein said compound has the formula Ib ##EQU34## wherein R 1b is loweralkoxy loweralkoxy, R 2b is carbamoyl, loweralkylcarbamoyl or diloweralkylcarbamoyl and R 5b is hydrogen, halogen, loweralkyl, loweralkenyl, loweralkoxy-methyl, loweralkoxy or loweralkenyloxy.
Claim 23
Dependent Claim
35 words
A pharmaceutical composition according to claim 20 wherein R 1b is 2-ethoxyethoxy, 2-methoxyethoxy or 3-methoxy-n-propoxy, R 2b is carbamoyl, methylcarbamoyl or dimethylcarbamoyl, and R 5b is hydrogen, chloro, bromo, methyl, allyl, methoxymethyl, methoxy or allyloxy.
Claim 24
Dependent Claim
23 words
A pharmaceutical composition according to claim 20 wherein R 1b is 2-methoxyethoxy, R 2b is carbamoyl or N-methylcarbamoyl and R 5b is hydrogen.
Claim 25
Dependent Claim
19 words
A pharmaceutical composition according to claim 14 wherein said compound is in the form of a dextro-rotating optical antipode.
Claim 26
Dependent Claim
19 words
A pharmaceutical composition according to claim 14 wherein said compound is in the form of its levo-rotating optical antipode.
Claim 27
Dependent Claim
16 words
A pharmaceutical composition according to claim 14 wherein said compound is in a free base form.
Claim 28
Dependent Claim
21 words
A pharmaceutical composition according to claim 14 wherein said compound is in the form of a therapeutically acceptable acid addition salt.
Claim 29
Dependent Claim
12 words
A pharmaceutical composition according to claim 14 wherein said compound is 1-[4-(2-methoxyethoxy)-phenoxy]-2-hydroxy-3-[2-(N-methyl)-carbamoyl-1-methylethyl]-aminopropane.
Claim 30
Dependent Claim
12 words
A pharmaceutical composition according to claim 14 wherein said compound is 1-[4-(2-methoxyethoxy)-phenoxy]-2-hydroxy-3-(1-methyl-2-carbamoylethyl)-aminopropane.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-04-06 | 1979-10-06 | 1980-04-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-04-06 | 1983-10-06 | 1984-04-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-04-06 | 1987-10-06 | 1988-04-06 | $7700.00 | Window Closed / Lapsed |